Artificial Intelligence (AI) in Drug Discovery Market by Cover Page

Artificial Intelligence (AI) in Drug Discovery Market by Applications (Metabolic diseases, Cardiovascular diseases, Neurodegenerative diseases, Immuno-oncology, and Others), Offerings (Services and Software), Technology (Unsupervised Learning, Reinforcement Learning, Supervised Learning, Deep Learning, Machine Learning, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2022 – 2030

  • Report ID: ICT-SE-4526
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 199
  • Format:
  • Pub. Date: Upcoming
  • Share:

The artificial intelligence (AI) in drug discovery market size was valued at USD 897.5 million in 2021 and is projected to reach USD 9100 million by 2030, expanding at a CAGR of around 29.2% during the forecast period, 2022 – 2030. The growth of the market is attributed to the rising demand for the development of new medication therapies.


Artificial Intelligence (AI) in Drug Discovery Market by Summary

The use of AI solutions is being facilitated by the digitalization of the biomedical and clinical research fields. The use of AI-powered solutions is being boosted by the wide range of datasets produced by drug discovery processes including the molecular screening phase and preclinical research. Researchers struggle to accurately analyze the studies because of the enormous datasets, but AI solutions can speed up the screening procedures and shorten turnaround times. Additionally, the current Covid-19 pandemic has significantly changed how people see clinical trials and accelerated the adoption and use of AI solutions.

The market is being driven by the accessibility of numerous alternatives, including data mining and personalization capabilities, for using AI technologies in drug discovery procedures. In order to determine the molecular binding qualities of drug with high precision, deep learning and machine learning algorithms are integrated into AI platforms. Additionally, incorporating cutting-edge technologies like electronic data capture (EDC) helps manufacturers handle patient data better and lowers monitoring expenses. Integration of Electronic Clinical Outcome Assessment (e-COA) into AI technologies can reduce process mistakes. These cutting-edge AI solutions, which help stakeholders with data mining, patient recruiting, and the maintenance of medical and clinical records, are increasingly incorporating advanced analytics.

Preclinical testing is the stage of a clinical trial study that results in maximum revenue loss and low profits. The preclinical testing stage can be optimized to cut costs by implementing AI technology. AI-based models are used to precisely evaluate human physiological responses and reduce the need for expensive experimental testing.

Market Trends, Drivers, Restraints, and Opportunities

  • Stringent standards related to clinical trial research set down by regulatory agencies is projected to drive the market.
  • Increasing public-private partnerships are encouraging the usage of AI-powered technologies, which is expected to propel the market during the forecast period.
  • Implementation of AI solutions reduces the potential barriers and the length of the clinical trial cycle is minimized, this is anticipated to fuel the market in the coming years.
  • Integrating AI technology into current systems is a difficult task that requires intensive data processing, which is projected to hinder the market growth.
  • Lack of professional standards and certifications in AI/ML technology is estimated to hamper the market growth.
  • Government authorities in a number of developed and developing economies are implementing positive steps to enhance the adoption of AI solutions and clinical trials, which are anticipated to create immense growth opportunities during the forecast period.

Scope of the Report

The report on the global artificial intelligence in drug discovery market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Artificial Intelligence (AI) in Drug Discovery Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2021

Historic Data

2019–2020

Forecast Period

2022 – 2030

Segmentation

Applications (Metabolic diseases, Cardiovascular diseases, Neurodegenerative diseases, Immuno-oncology, and Others), Offerings (Services and Software), Technology (Unsupervised Learning, Reinforcement Learning, Supervised Learning, Deep Learning, Machine Learning, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

BenchSci; Standigm; Iktos; Owkin, Inc.; Verge Genomics; XtalPi; Envisagenics; BIOAGE; Deep Genomics; Google; Schrödinger; NVIDIA Corporation; Valo Health; Insitro; IBM Watson; GNS Healthcare; Exscientia; Euretos; Cyclica; BioSymetrics; Berg Health; Benevolent AI; Atomwise; Microsoft Corporation; and Alphabet (DeepMind).

Market Segment Insights

The neurodegenerative diseases segment is projected to expand at a high CAGR

Based on applications, the market is segregated into metabolic diseases, cardiovascular diseases, neurodegenerative diseases, immuno-oncology, and others. The neurodegenerative diseases segment is projected to expand at a high CAGR during the forecast period. Growth rate of the neurodegenerative illnesses sector can be attributed to the potential of AI to develop treatments for inflammatory traits and the focus of market players on delivering AI-based platforms for neurological diseases.


Artificial Intelligence (AI) in Drug Discovery Market by Applications

The services segment is estimated to grow at a rapid pace during the forecast period

On the basis of offerings, the market is bifurcated into services and software. The services segment is estimated to grow at a rapid pace during the forecast period. The growth of the segment is attributed to advantages of AI services and the high demand for AI services among end users.

The deep learning segment held major market share in 2021

In terms of technology, the market is fragmented into unsupervised learning, reinforcement learning, supervised learning, deep learning, machine learning, and others. The deep learning segment held major market share in 2021 and is projected to maintain its dominance during the forecast period. Deep learning assists in reducing the workload of end-users, lowers the risk of mistakes during the drug discovery process, and speeds up data management these factors are estimated to boost the segment.

North America dominated the market in 2021

On the basis of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America dominated the market in 2021 and held around 52% of the total market share. To accelerate medication research, design, and repurposing, major tech corporations in the United States have all partnered with esteemed institutions. Additionally, they are utilizing AI to research diseases and draw insightful conclusions that can enhance disease management.


Artificial Intelligence (AI) in Drug Discovery Market by Regions

Segments

The global artificial intelligence in drug discovery market has been segmented on the basis of

Applications
  • Metabolic diseases
  • Cardiovascular diseases
  • Neurodegenerative diseases
  • Immuno-oncology
  • Others
Offerings
  • Services
  • Software
Technology
  • Unsupervised Learning
  • Reinforcement Learning
  • Supervised Learning
  • Deep Learning
  • Machine Learning
  • Others
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • BenchSci
  • Standigm
  • Iktos
  • Owkin, Inc.
  • Verge Genomics
  • XtalPi
  • Envisagenics
  • BIOAGE
  • Deep Genomics
  • Google
  • Schrödinger
  • NVIDIA Corporation
  • Valo Health
  • Insitro
  • IBM Watson
  • GNS Healthcare
  • Exscientia
  • Euretos
  • Cyclica
  • BioSymetrics
  • Berg Health
  • Benevolent AI
  • Atomwise
  • Microsoft Corporation
  • Alphabet (DeepMind)

Competitive Landscape

Key players competing in the artificial intelligence in drug discovery market include BenchSci; Standigm; Iktos; Owkin, Inc.; Verge Genomics; XtalPi; Envisagenics; BIOAGE; Deep Genomics; Google; Schrödinger; NVIDIA Corporation; Valo Health; Insitro; IBM Watson; GNS Healthcare; Exscientia; Euretos; Cyclica; BioSymetrics; Berg Health; Benevolent AI; Atomwise; Microsoft Corporation; and Alphabet (DeepMind). Some of these players are using several market strategies such as acquisitions, mergers, collaborations, partnerships, capacity expansion, and product launches to enhance their market shares, generate revenue, and raise their production line of the business in the coming years. For instance,

  • In March 2021, Iktos and Pfizer worked together to deploy Iktos' AI-driven de novo design software to a few of Pfizer's small-molecule initiatives.
  • In February 2021, The University of Oxford and Exscientia (UK) worked together to create treatments for Alzheimer's disease.
Artificial Intelligence (AI) in Drug Discovery Market by Key Players
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Artificial Intelligence (AI) in Drug Discovery Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Artificial Intelligence (AI) in Drug Discovery Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Artificial Intelligence (AI) in Drug Discovery Market - Supply Chain
  4.5. Global Artificial Intelligence (AI) in Drug Discovery Market Forecast
     4.5.1. Artificial Intelligence (AI) in Drug Discovery Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Artificial Intelligence (AI) in Drug Discovery Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Artificial Intelligence (AI) in Drug Discovery Market Absolute $ Opportunity
5. Global Artificial Intelligence (AI) in Drug Discovery Market Analysis and Forecast by Applications
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Applications
     5.2.2. Y-o-Y Growth Projections by Applications
  5.3. Artificial Intelligence (AI) in Drug Discovery Market Size and Volume Forecast by Applications
     5.3.1. Metabolic diseases
     5.3.2. Cardiovascular diseases
     5.3.3. Neurodegenerative diseases
     5.3.4. Immuno-oncology
     5.3.5. Others
  5.4. Absolute $ Opportunity Assessment by Applications
  5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Artificial Intelligence (AI) in Drug Discovery Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Artificial Intelligence (AI) in Drug Discovery Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Artificial Intelligence (AI) in Drug Discovery Demand Share Forecast, 2019-2026
7. North America Artificial Intelligence (AI) in Drug Discovery Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Artificial Intelligence (AI) in Drug Discovery Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Artificial Intelligence (AI) in Drug Discovery Market Size and Volume Forecast by Applications
     7.4.1. Metabolic diseases
     7.4.2. Cardiovascular diseases
     7.4.3. Neurodegenerative diseases
     7.4.4. Immuno-oncology
     7.4.5. Others
  7.5. Basis Point Share (BPS) Analysis by Applications
  7.6. Y-o-Y Growth Projections by Applications
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Artificial Intelligence (AI) in Drug Discovery Demand Share Forecast, 2019-2026
8. Latin America Artificial Intelligence (AI) in Drug Discovery Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Artificial Intelligence (AI) in Drug Discovery Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Artificial Intelligence (AI) in Drug Discovery Market Size and Volume Forecast by Applications
     8.4.1. Metabolic diseases
     8.4.2. Cardiovascular diseases
     8.4.3. Neurodegenerative diseases
     8.4.4. Immuno-oncology
     8.4.5. Others
  8.5. Basis Point Share (BPS) Analysis by Applications
  8.6. Y-o-Y Growth Projections by Applications
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Artificial Intelligence (AI) in Drug Discovery Demand Share Forecast, 2019-2026
9. Europe Artificial Intelligence (AI) in Drug Discovery Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Artificial Intelligence (AI) in Drug Discovery Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Artificial Intelligence (AI) in Drug Discovery Market Size and Volume Forecast by Applications
     9.4.1. Metabolic diseases
     9.4.2. Cardiovascular diseases
     9.4.3. Neurodegenerative diseases
     9.4.4. Immuno-oncology
     9.4.5. Others
  9.5. Basis Point Share (BPS) Analysis by Applications
  9.6. Y-o-Y Growth Projections by Applications
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Artificial Intelligence (AI) in Drug Discovery Demand Share Forecast, 2019-2026
10. Asia Pacific Artificial Intelligence (AI) in Drug Discovery Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Artificial Intelligence (AI) in Drug Discovery Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Artificial Intelligence (AI) in Drug Discovery Market Size and Volume Forecast by Applications
     10.4.1. Metabolic diseases
     10.4.2. Cardiovascular diseases
     10.4.3. Neurodegenerative diseases
     10.4.4. Immuno-oncology
     10.4.5. Others
  10.5. Basis Point Share (BPS) Analysis by Applications
  10.6. Y-o-Y Growth Projections by Applications
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Artificial Intelligence (AI) in Drug Discovery Demand Share Forecast, 2019-2026
11. Middle East & Africa Artificial Intelligence (AI) in Drug Discovery Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Artificial Intelligence (AI) in Drug Discovery Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Artificial Intelligence (AI) in Drug Discovery Market Size and Volume Forecast by Applications
     11.4.1. Metabolic diseases
     11.4.2. Cardiovascular diseases
     11.4.3. Neurodegenerative diseases
     11.4.4. Immuno-oncology
     11.4.5. Others
  11.5. Basis Point Share (BPS) Analysis by Applications
  11.6. Y-o-Y Growth Projections by Applications
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Artificial Intelligence (AI) in Drug Discovery Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Artificial Intelligence (AI) in Drug Discovery Market: Market Share Analysis
  12.2. Artificial Intelligence (AI) in Drug Discovery Distributors and Customers
  12.3. Artificial Intelligence (AI) in Drug Discovery Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. BenchSci
     12.4.2. Standigm
     12.4.3. Iktos
     12.4.4. Owkin, Inc.
     12.4.5. Verge Genomics
     12.4.6. XtalPi
     12.4.7. Envisagenics
     12.4.8. BIOAGE

The global artificial intelligence in drug discovery market has been segmented on the basis of

Applications
  • Metabolic diseases
  • Cardiovascular diseases
  • Neurodegenerative diseases
  • Immuno-oncology
  • Others
Offerings
  • Services
  • Software
Technology
  • Unsupervised Learning
  • Reinforcement Learning
  • Supervised Learning
  • Deep Learning
  • Machine Learning
  • Others
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • BenchSci
  • Standigm
  • Iktos
  • Owkin, Inc.
  • Verge Genomics
  • XtalPi
  • Envisagenics
  • BIOAGE
  • Deep Genomics
  • Google
  • Schrödinger
  • NVIDIA Corporation
  • Valo Health
  • Insitro
  • IBM Watson
  • GNS Healthcare
  • Exscientia
  • Euretos
  • Cyclica
  • BioSymetrics
  • Berg Health
  • Benevolent AI
  • Atomwise
  • Microsoft Corporation
  • Alphabet (DeepMind)

Key players competing in the artificial intelligence in drug discovery market include BenchSci; Standigm; Iktos; Owkin, Inc.; Verge Genomics; XtalPi; Envisagenics; BIOAGE; Deep Genomics; Google; Schrödinger; NVIDIA Corporation; Valo Health; Insitro; IBM Watson; GNS Healthcare; Exscientia; Euretos; Cyclica; BioSymetrics; Berg Health; Benevolent AI; Atomwise; Microsoft Corporation; and Alphabet (DeepMind). Some of these players are using several market strategies such as acquisitions, mergers, collaborations, partnerships, capacity expansion, and product launches to enhance their market shares, generate revenue, and raise their production line of the business in the coming years. For instance,

  • In March 2021, Iktos and Pfizer worked together to deploy Iktos' AI-driven de novo design software to a few of Pfizer's small-molecule initiatives.
  • In February 2021, The University of Oxford and Exscientia (UK) worked together to create treatments for Alzheimer's disease.
Artificial Intelligence (AI) in Drug Discovery Market by Key Players

Buy Report

FAQ Section

Some frequently asked quetions about this report!

The artificial intelligence (AI) in drug discovery market is anticipated to expand at a CAGR of around 29.2% during the forecast period, 2022 – 2030.

The artificial intelligence (AI) in drug discovery market is projected to reach USD 9100 million by 2030.

The artificial intelligence (AI) in drug discovery market size was valued at USD 897.5 million in 2021.

North America dominated the artificial intelligence (AI) in drug discovery market in 2021.

Metabolic diseases, Cardiovascular diseases, Neurodegenerative diseases, Immuno-oncology, and Others are the applications of artificial intelligence (AI) in drug discovery market.